Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
RAD-150 (TLB-150), (10mg/capsule) 60 Capsules
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
RAD-150 (TLB-150) is a benzoate ester derivative of RAD-140 (Testolone) designed as a prodrug that undergoes ester hydrolysis to release RAD-140 as the active androgen receptor (AR) agonist. The addition of the benzoate ester modifies the physicochemical properties of the parent molecule, making RAD-150 a useful research tool for investigating prodrug design strategies, esterification chemistry, and metabolic conversion mechanisms. Experimental studies have examined its interactions with AR-mediated signaling pathways, ligand-receptor binding dynamics, and receptor-associated transcriptional regulation following conversion to the active species. Research applications include prodrug pharmacology, ester hydrolysis studies, androgen receptor signaling investigation, structure-activity relationship analysis, and mechanistic evaluation of esterified androgen receptor modulators.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C27H20ClN5O3 |
|---|---|
| Synonyms | TLB-150 Benzoate, RAD-140 Benzoate ester |
| Molar Mass | 497.93 g/mol |
| CAS Number | 1208070-53-4 |
| PubChem CID | 68547459 |
| Total Compound Content | 600 mg (10 mg per capsule) |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
What is the rationale for esterifying RAD-140 to produce RAD-150?
RAD-150 incorporates a benzoate ester modification of the RAD-140 scaffold, creating a prodrug designed for metabolic conversion to the parent compound. This esterification alters the physicochemical and metabolic characteristics of the molecule, making RAD-150 a useful research tool for investigating prodrug design strategies, ester hydrolysis mechanisms, and the impact of structural modification on compound disposition. Such approaches are commonly used in medicinal chemistry to examine how ester derivatives influence the behavior of parent compounds.
Is RAD-150 itself pharmacologically active, or does it require conversion to RAD-140?
RAD-150 functions primarily as a prodrug that undergoes ester hydrolysis to release RAD-140. The conversion process is central to its research utility, allowing investigators to examine metabolic activation pathways, prodrug pharmacology, and the relationship between esterified compounds and their active metabolites. Following hydrolysis, the released RAD-140 retains its characteristic androgen receptor interaction profile, making RAD-150 a valuable tool for studies of compound conversion and receptor-mediated signaling.
What distinguishes RAD-150 from other SARMs in pharmacology research?
RAD-150 is distinguished by its esterified prodrug design, whereas most SARMs are investigated in their active, non-esterified forms. This characteristic makes RAD-150 useful for studies examining esterification chemistry, metabolic conversion mechanisms, structure-activity relationships, and comparative pharmacology between parent compounds and ester derivatives. Its design provides a distinct model for investigating how chemical modification influences the properties of androgen receptor modulators.
-
-
-
SALE
-
-
SALE
-
SALE
-
-
